Chemo-Pharma [CPL] vs Nippon Life India [NAM] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Chemo-Pharma Laboratories Inc. wins in 13 metrics, Nippon Life India Asset Management Limited wins in 6 metrics, with 0 ties. Chemo-Pharma Laboratories Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma Laboratories Inc. | Nippon Life India Asset Management Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.22 | 186.84 | Chemo-Pharma Laboratories Inc. |
| Price-to-Book Ratio | 2.69 | 3.31 | Chemo-Pharma Laboratories Inc. |
| Debt-to-Equity Ratio | 48.02 | 1.70 | Nippon Life India Asset Management Limited |
| PEG Ratio | 0.42 | -5.61 | Chemo-Pharma Laboratories Inc. |
| EV/EBITDA | 13.60 | 48.03 | Chemo-Pharma Laboratories Inc. |
| Profit Margin (TTM) | 6.53% | 0.53% | Chemo-Pharma Laboratories Inc. |
| Operating Margin (TTM) | 11.52% | 0.71% | Chemo-Pharma Laboratories Inc. |
| EBITDA Margin (TTM) | 11.52% | 0.71% | Chemo-Pharma Laboratories Inc. |
| Return on Equity | 20.97% | 3.14% | Chemo-Pharma Laboratories Inc. |
| Return on Assets (TTM) | 11.26% | 3.01% | Chemo-Pharma Laboratories Inc. |
| Free Cash Flow (TTM) | $41.66M | $-8.13M | Chemo-Pharma Laboratories Inc. |
| 1-Year Return | -5.34% | 1.28% | Nippon Life India Asset Management Limited |
| Price-to-Sales Ratio (TTM) | 1.31 | 1.01 | Nippon Life India Asset Management Limited |
| Enterprise Value | $5.40B | $306.80M | Chemo-Pharma Laboratories Inc. |
| EV/Revenue Ratio | 1.52 | 0.81 | Nippon Life India Asset Management Limited |
| Gross Profit Margin (TTM) | 24.93% | 1.95% | Chemo-Pharma Laboratories Inc. |
| Revenue per Share (TTM) | $62 | $70 | Nippon Life India Asset Management Limited |
| Earnings per Share (Diluted) | $5.81 | $0.38 | Chemo-Pharma Laboratories Inc. |
| Beta (Stock Volatility) | 0.28 | 0.23 | Nippon Life India Asset Management Limited |
Chemo-Pharma Laboratories Inc. vs Nippon Life India Asset Management Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma Laboratories Inc. | 0.43% | -0.20% | -9.72% | 10.04% | -11.06% | -12.31% |
| Nippon Life India Asset Management Limited | -4.75% | 0.08% | -9.29% | -10.65% | -17.67% | -5.95% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma Laboratories Inc. | -5.34% | 232.23% | 82.57% | 325.71% | 1,271.09% | 1,271.09% |
| Nippon Life India Asset Management Limited | 1.28% | 43.62% | 102.29% | 130.39% | 395.16% | 395.16% |
Performance & Financial Health Analysis: Chemo-Pharma Laboratories Inc. vs Nippon Life India Asset Management Limited
| Metric | CPL | NAM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.62B | ₹402.03M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 97,700 | 335 |
| 90 Day Avg. Volume | 68,661 | 321 |
| Last Close | ₹70.50 | ₹79.00 |
| 52 Week Range | ₹52.67 - ₹87.75 | ₹68.00 - ₹105.30 |
| % from 52W High | -19.66% | -24.98% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹198.00 (Sep 02, 2024) |
| % from All-Time High | -44.92% | -60.10% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.40% | 0.03% |
| Quarterly Earnings Growth | 0.41% | -0.36% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.01% |
| Operating Margin (TTM) | 0.12% | 0.01% |
| Return on Equity (TTM) | 0.21% | 0.03% |
| Debt to Equity (MRQ) | 48.02 | 1.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹28.58 | ₹21.47 |
| Cash per Share (MRQ) | ₹0.05 | ₹13.23 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹16.34M |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹3.57M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma Laboratories Inc. vs Nippon Life India Asset Management Limited
| Metric | CPL (Apr 26, 2026) | NAM (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.22 | 186.84 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.42 | -5.61 |
| Price to Sales (TTM) | 1.31 | 1.01 |
| Price to Book (MRQ) | 2.69 | 3.31 |
| Market Capitalization | ||
| Market Capitalization | ₹4.62B | ₹402.03M |
| Enterprise Value | ₹5.40B | ₹306.80M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.52 | 0.81 |
| Enterprise to EBITDA | 13.60 | 48.03 |
| Risk & Other Metrics | ||
| Beta | 0.28 | 0.23 |
| Book Value per Share (MRQ) | ₹28.58 | ₹21.47 |
Financial Statements Comparison: Chemo-Pharma Laboratories Inc. vs Nippon Life India Asset Management Limited
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | CPL (2025) | NAM (2025) |
|---|---|---|
| Revenue/Sales | 2.85B | 666.09M |
| Cost of Goods Sold | 2.07B | 652.72M |
| COGS % of Revenue | 72.6% | 98.0% |
| Gross Profit | 778.98M | 13.38M |
| Gross Margin | 27.4% | 2.0% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 300.69M | 3.95M |
| Operating Margin | 10.6% | 0.6% |
| EBITDA | 353.29M | 6.39M |
| EBITDA Margin | 12.4% | 1.0% |
| Pre-Tax Income | 392.47M | 4.77M |
| Pre-Tax Income % of Revenue | 13.8% | 0.7% |
| Income Tax | 79.24M | 1.20M |
| Income Tax % of Revenue | 2.8% | 0.2% |
| Net Income (Profit) | 313.23M | 3.57M |
| Profit Margin | 11.0% | 0.5% |
Balance Sheet & Liquidity Metrics
| Metric | CPL (2025) | NAM (2025) |
|---|---|---|
| Cash & Equivalents | 12.05M | 1.50M |
| Total Current Assets | 2.51B | 94.28M |
| Total Current Assets % of Revenue | 88.1% | 14.2% |
| Total Current Liabilities | 1.17B | 3.96M |
| Total Current Liabilities % of Revenue | 41.2% | 0.6% |
| Long-Term Debt | 109.50M | 0 |
| Long-Term Debt % of Revenue | 3.8% | 0.0% |
| Total Shareholders Equity | 1.49B | 113.51M |
| Retained Earnings | 1.08B | 29.69M |
| Retained Earnings % of Revenue | 37.9% | 4.5% |
| Property, Plant & Equipment | 48.61M | 24.14M |
Cash Flow Statement Comparison
| Metric | CPL (2025) | NAM (2025) |
|---|---|---|
| Operating Cash Flow | 277.99M | 16.34M |
| Operating Cash Flow % of Revenue | 9.8% | 2.5% |
| Capital Expenditures | -47.82M | -19.06M |
| Free Cash Flow | 41.66M | -8.13M |
| FCF Margin | 1.5% | -1.2% |
| Debt Repayment | -359.80M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | NAM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 60.18M | 5.39M |
| Float Shares | 17.41M | 389,137 |
| % Held by Insiders | 69.98% | 90.00% |
| % Held by Institutions | 0.00% | 0.00% |
| % Held by Public | 30.02% | 10.00% |
Dividend Analysis & Yield Comparison: Chemo-Pharma Laboratories Inc. vs Nippon Life India Asset Management Limited
| Metric | CPL | NAM |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |